Global Liraglutide And Semaglutide Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Liraglutide And Semaglutide Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Liraglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 receptor agonist) also known as incretin mimetics. It works by increasing insulin release from the pancreas and decreasing excessive glucagon release. Liraglutide was approved for medical use in the European Union in 2009, and in the United States in 2010.

Semaglutide, sold under the brand name Ozempic among others, is an anti-diabetic medication used for the treatment of type 2 diabetes and chronic weight management.

Semaglutide acts like human glucagon-like peptide-1 (GLP-1) such that it increases insulin secretion, thereby increasing sugar metabolism. It is distributed as a metered subcutaneous injection in a prefilled pen or as an oral form. One of its advantages over other antidiabetic drugs is that it has a long duration of action, thus, only a once-a-week injection is sufficient.

Market Overview:

The latest research study on the global Liraglutide And Semaglutide market finds that the global Liraglutide And Semaglutide market reached a value of USD 8226.0 million in 2022. It’s expected that the market will achieve USD 15042.16 million by 2028, exhibiting a CAGR of 10.58% during the forecast period.

Influence of COVID-19 Outbreak on Liraglutide and Semaglutide Industry Development

Although the epidemic has seriously affected the global economy, the market development of Liraglutide and Semaglutide remains on the rise.

The spread of covid-19 has dealt a great blow to Novo Nordisk's North American market. In 2020, Novo Nordisk's revenue was US$ 20.31 billion, which increased by 6.7% year-on-year, excluding the influence of exchange rate, which was mainly driven by the rapid growth of Semaglutide. China and Europe maintained steady growth, while the North American market was greatly affected by policies and epidemics, which dragged down the overall performance.

After the patent expires, the market competition is fierce.

The main patent for Liraglutide has expired in China, and the American patent will expire in 2023. From 2020 to 2024, pharmaceutical manufacturers in various countries mainly compete around R&D efficiency and production reporting schedule. Enterprises with rapid R&D are in the final stage of Phase III clinical practice. Some pharmaceutical companies are already applying for clinical trials for other indications. In addition to Liraglutide, studies have been carried out on Semaglutide, a weekly preparation of GLP1, and oral preparations of weekly preparations, all of which will obtain marketing licenses after the patent period expires. Globally, the growth of GLP-1 receptor agonists will be much higher than the overall growth of insulin products in the future, which is also a new market opened by major manufacturers in the field of diabetes besides insulin. The whole market competition between Liraglutide and Semaglutide will become increasingly fierce after the patent expires.

Good performance

Both Liraglutide and Semaglutide are GLP-1 receptor agonists. Compared with traditional hypoglycemic agents, liraglutide can not only promote insulin secretion and reduce glucagon secretion but also slow down gastric emptying and suppress appetite. Studies have shown that liraglutide can significantly reduce body weight, especially the weight of visceral liver, while lowering blood sugar, which is more obvious for people with higher BMI. Liraglutide is also approved for cardiovascular indications.

Region Overview:

North America had the highest growth rate of all regions.

Company Overview:

Novo Nordisk is one of the major players operating in the Liraglutide And Semaglutide market, holding a share of 100% in 2022.

Segmentation Overview:

Among different product types, Liraglutide segment is anticipated to contribute the largest market share in 2027.

Application Overview:

By application, the Drug Store segment occupied the biggest share from 2017 to 2022.

Key Companies in the global Liraglutide And Semaglutide market covered in Chapter 3:

Novo Nordisk

In Chapter 4 and Chapter 14.2, on the basis of types, the Liraglutide And Semaglutide market from 2018 to 2029 is primarily split into:

Liraglutide
Semaglutide

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Liraglutide And Semaglutide market from 2018 to 2029 covers:

Hospital
Drug Store

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)